Aroa Biosurgery Ltd (AU:ARX) has released an update.
Aroa Biosurgery Ltd has reported a solid fiscal year 2023, with a notable 12% increase in total revenue and a 73% surge in Myriad product revenue, reaching $23.3 million, alongside a modest 1% growth in gross margin. The company also successfully completed its first clinical pilot study for Enivo.
For further insights into AU:ARX stock, check out TipRanks’ Stock Analysis page.
